Abstract
Advanced ovarian cancer remains a significant clinical challenge, often requiring neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). This systematic review and meta-analysis evaluates the efficacy and safety of adding bevacizumab to standard NACT. Analyzing data from five studies (n=371), the study found that while the addition of bevacizumab is safe and does not increase postoperative complications, it does not significantly improve optimal cytoreduction rates or progression-free survival (PFS) compared to standard chemotherapy alone.
Introduction
Ovarian cancer is the leading cause of death among gynecological malignancies, primarily because most patients are diagnosed at advanced stages (FIGO III or IV). The standard treatment paradigm involves neoadjuvant chemotherapy (NACT)—typically paclitaxel and carboplatin (TC)—to reduce tumor burden before interval debulking surgery (IDS). The goal of IDS is to achieve R0 resection (no visible residual tumor).
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has proven effective as a maintenance therapy. However, its use in the neoadjuvant setting is debated. Clinicians are concerned that its anti-angiogenic properties might interfere with wound healing or cause gastrointestinal perforations, thereby increasing surgical risk. This meta-analysis seeks to determine if the potential for improved tumor shrinkage outweighs these safety concerns.
Methodology
This study followed PRISMA guidelines to identify relevant clinical trials and cohort studies. Researchers searched major databases, including PubMed, Embase, and the Cochrane Library, for studies comparing bevacizumab plus TC (TCB) against TC alone in the neoadjuvant setting.
Five studies published between 2017 and 2022 met the inclusion criteria, comprising three randomized controlled trials (RCTs) and two high-quality cohort studies. The total population included 371 patients (160 in the TCB group and 211 in the TC group). Statistical analysis was performed using Stata 15.0 and RevMan 5.4, utilizing fixed-effects or random-effects models based on the degree of heterogeneity ($I^2$).
Results
Efficacy: Tumor Reduction and Survival
The primary efficacy metric was the rate of optimal cytoreduction. The analysis yielded a Relative Risk (RR) of 1.124 (95% CI: 0.947–1.335, $p = 0.182$), suggesting that bevacizumab did not significantly increase the likelihood of achieving a satisfactory surgical outcome.
Regarding progression-free survival (PFS), the pooled Hazard Ratio (HR) was 0.74 (95% CI: 0.48–1.14, $p = 0.173$). Although the point estimate favors the TCB group, the result did not reach statistical significance, and high heterogeneity ($I^2 = 86.0%$) was observed among the reporting studies.
Safety and Complications
A critical finding of this meta-analysis is the safety profile of neoadjuvant bevacizumab. There was no statistically significant difference in the incidence of chemotherapy-related adverse events (RR = 0.88, $p = 0.238$) or postoperative complications (RR = 0.955, $p = 0.799$). This suggests that the feared "leaky" surgical sites and healing delays associated with anti-angiogenic therapy may not be as prevalent in this specific clinical context as previously thought.
Discussion and Conclusion
The results indicate that while adding bevacizumab to NACT is safe and feasible, it does not provide a clear clinical advantage in terms of surgical success or short-term survival. The lack of PFS improvement suggests that the biological benefits of VEGF inhibition might be better realized during the maintenance phase following surgery, rather than in the preemptive phase.
Limitations of this study include a relatively small total sample size and significant heterogeneity in PFS reporting. Future research should focus on larger, multi-center prospective RCTs to identify specific patient subgroups—such as those with high volumes of ascites—who might derive a more pronounced benefit from neoadjuvant bevacizumab. For now, its use in NACT should be carefully considered on a case-by-case basis rather than adopted as a universal standard of care.
Summary updated